spiro-mamakone A: spirobisnaphthalene derivative with a spiro-nonadiene skeleton from cultured nonsporulating fungal endophyte derived from the New Zealand native tree Knightia excelsa (rewarewa); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Knightia | genus | [no description available] | Proteaceae | A plant family of the order Proteales, subclass Rosidae class Magnoliopsida. Cluster roots, bottlebrush-like clusters of rootlets which form in response to poor soil, are common in this family.[MeSH] |
| Knightia excelsa | species | [no description available] | Proteaceae | A plant family of the order Proteales, subclass Rosidae class Magnoliopsida. Cluster roots, bottlebrush-like clusters of rootlets which form in response to poor soil, are common in this family.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 11709529 |
| CHEMBL ID | 2414478 |
| MeSH ID | M0506679 |
| Synonym |
|---|
| CHEMBL2414478 |
| spiro-mamakone a |
| 889098-19-5 |
| DTXSID601047548 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID763710 | Cytotoxicity against human HeLa cells assessed as cell survival after 48 hrs by WST-8 method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Design and synthesis of 2-phenyl-1,4-dioxa-spiro[4.5]deca-6,9-dien-8-ones as potential anticancer agents starting from cytotoxic spiromamakone A. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||